# Verastem, Inc.

**VSTM**

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001526119

**B**

**second fifth of 370 graded peers in healthcare**

rank 119 of 370; percentile 32.0; sampling error 2.5 points; lower is stronger

A B C D E

**B, the elk**



| Scoreboard | |
|---|---|
| **Profitability** | A<br>percentile 10.2 |
| **Solvency** | D<br>percentile 72.1 |
| **Growth and financing** | C<br>percentile 45.8 |
| **Reliability** | 0.87 AUC<br>filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025 |
| **Peer failure rate** | 1.03% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $120M to $591M assets<br>total assets $246.4M |
| **Standard universe** | inside<br>revenue above $1M and assets above $10M |
| **Warnings** | dilution; fortress balance sheet |
| **Inputs computable** | 7 of 14 |
| **Graded from** | filings received through Mar 4, 2026<br>236 days before the rescan; latest periodic filing 10-Q received Aug 6, 2026 |
| **Last close** | $10.04<br>2026-10-23; market equity $909.3M; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Mar 4, 2026*

We are a biopharmaceutical company committed to developing and commercializing new medicines to improve the lives of patients diagnosed with challenging RAS/MAPK pathway-driven cancers. We market AVMAPKI FAKZYNJA CO-PACK (avutometinib capsules; defactinib tablets) in the United States ("U.S."), the first treatment specifically FDA-approved for adults with KRAS-mutated recurrent low-grade serous ovarian cancer ("LGSOC") who have received prior systemic therapy. AVMAPKI FAKZYNJA CO-PACK received accelerated approval in the U.S. on May 8, 2025.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 10.2** | | | | | | |
| Gross profitability | not computable | 32.3% | | | | |
| *latest aligned inputs end 2018-12-31; latest annual assets end 2025-12-31* | | | | | | |
| Return on invested capital | not computable | 9.3% | | | | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | |
|---|---|---|---|---|---|---|
| *pretax income must exceed the validity floor and imply a 0%-100% tax rate* | | | | | | |
| Accruals ratio | (41.4%) | (6.6%) | 10.2 | 807 | 2025-12-31 | |
| Gross margin stability, five years | not computable | 2.8 pts | | | | |
| *five annual gross margins are required; found 1* | | | | | | |
| **Solvency, sleeve percentile 72.1** | | | | | | |
| Twelve-month failure probability | 0.18% | 0.07% | 67.6 | 248 | 2026-06-30 | |
| Altman Z double-prime | (15.71) | (0.33) | 70.7 | 752 | 2025-12-31 | |
| Net debt to EBITDA | not computable | 1.82x | | | | |
| *EBITDA must exceed $100,000* | | | | | | |
| Interest coverage | (149.50x) | (4.51x) | 95.0 | 81 | 2025-12-31 | |
| Current ratio | 3.09x | 2.94x | 55.2 | 834 | 2025-12-31 | |
| **Growth and financing, sleeve percentile 45.8** | | | | | | |
| Revenue growth, three-year compound | not computable | 10.1% | | | | |
| *four consecutive annual observations are required* | | | | | | |
| Free cash flow growth, three-year compound | not computable | 10.9% | | | | |
| *four consecutive annual FCF observations are required; found 10* | | | | | | |
| Reinvestment rate | not computable | 37.1% | | | | |
| *pretax income must exceed the validity floor and imply a 0%-100% tax rate* | | | | | | |
| Asset growth, three years | 37.4% | 2.1% | 12.0 | 700 | 2025-12-31 | |
| Net share issuance, one year | 70.6% | 2.5% | 79.5 | 636 | 2026-02-27 | |

## Warnings

*2 of 7 checks triggered; none of them enters the letter*

| Check | Measured |
|---|---|
| Dilution | split-adjusted year-over-year share growth is 70.6% |
| Fortress balance sheet | cash minus debt is 48,094,000 USD; Altman Z is not used |

## Among 370 peers

*healthcare; letters are fifths of this list*




*Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.*

| Rank | Company | Percentile | Letter | Warnings |
|---|---|---|---|---|
| 114 | BioNexus Gene Lab Corp. (BGLC) | 30.6 | B | dilution, late filer |
| 115 | Arcutis Biotherapeutics, Inc. (ARQT) | 30.9 | B | |
| 116 | Bio-Techne Corp. (TECH) | 31.2 | B | fortress balance sheet |
| 117 | Stryker Corp. (SYK) | 31.4 | B | |
| 118 | Usana Health Sciences Inc. (USNA) | 31.7 | B | |
| 119 | Verastem, Inc. (VSTM) | 32.0 | B | dilution, fortress balance sheet |
| 120 | Eton Pharmaceuticals, Inc. (ETON) | 32.2 | B | |
| 121 | CVRx, Inc. (CVRX) | 32.5 | B | |
| 122 | Koru Medical Systems, Inc. (KRMD) | 32.8 | B | fortress balance sheet |
| 123 | CorMedix Inc. (CRMD) | 33.1 | B | |
| 124 | InfuSystem Holdings, Inc. (INFU) | 33.3 | B | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

## What the price implies

*at the 2026-10-23 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | (18.2%) | 7.7% | 31 |
| Distance from 52-week high | (5.6%) | (31.4%) | 84 |
| EBIT to enterprise value | (20.9%) | (1.5%) | 23 |
| Free cash flow yield | (11.5%) | (1.0%) | 30 |
| Book value to price | 0.05 | 0.28 | 20 |
| Sales to price | 0.03 | 0.30 | 12 |
| Composite equity issuance, five years | 184.5% | 20.5% | 87 |
| Relative strength against the sector, log excess return | (0.41) | (0.14) | 31 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | fail |
| Return on assets improved | fail |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | fail |
| Current ratio improved | pass |
| No new shares issued | fail |
| Gross margin improved | fail |
| Asset turnover improved | pass |
| **Cash, filings, liquidity** | |
| Cash and equivalents | $136.4M |
| Operating cash flow, four quarters | -$162.2M |
| Months of runway | 10.1 |
| Days since last periodic filing | 81 (10-Q received Aug 6, 2026) |
| Median daily dollar volume, 63 sessions | $15.8M |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $26.7M | 2018-12-31 | 2021-03-18 | 10-K | 21-003211 |
| 2 | cost of revenue | us-gaap:CostOfGoodsAndServicesSold | $165,000 | 2018-12-31 | 2019-03-12 | 10-K | 19-001852 |
| 3 | assets | us-gaap:Assets | $277.2M | 2018-12-31 | 2020-03-11 | 10-K | 20-002421 |
| 4 | operating income | us-gaap:OperatingIncomeLoss | -$115.0M | 2024-12-31 | 2026-03-04 | 10-K | 26-023444 |
| 5 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | -$130.5M | 2024-12-31 | 2026-03-04 | 10-K | 26-023444 |
| 6 | income tax | us-gaap:IncomeTaxExpenseBenefit | $185,000 | 2024-12-31 | 2026-03-04 | 10-K | 26-023444 |
| 7 | total debt | us-gaap:LongTermDebt | $40.7M | 2024-12-31 | 2026-03-04 | 10-K | 26-023444 |
| 8 | book equity | us-gaap:StockholdersEquity | -$28.9M | 2024-12-31 | 2026-03-04 | 10-K | 26-023444 |
| 9 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $88.8M | 2024-12-31 | 2026-03-04 | 10-K | 26-023444 |
| 10 | total debt | us-gaap:LongTermDebt | $40.1M | 2023-12-31 | 2025-03-20 | 10-K | 25-003372 |
| 11 | book equity | us-gaap:StockholdersEquity | $57.4M | 2023-12-31 | 2026-03-04 | 10-K | 26-023444 |
| 12 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $77.9M | 2023-12-31 | 2025-03-20 | 10-K | 25-003372 |
| 13 | net income | us-gaap:NetIncomeLoss | -$209.5M | 2025-12-31 | 2026-03-04 | 10-K | 26-023444 |
| 14 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$137.5M | 2025-12-31 | 2026-03-04 | 10-K | 26-023444 |
| 15 | assets | us-gaap:Assets | $246.4M | 2025-12-31 | 2026-03-04 | 10-K | 26-023444 |
| 16 | assets | us-gaap:Assets | $101.5M | 2024-12-31 | 2026-03-04 | 10-K | 26-023444 |
| 17 | current assets | us-gaap:AssetsCurrent | $223.4M | 2025-12-31 | 2026-03-04 | 10-K | 26-023444 |
| 18 | current liabilities | us-gaap:LiabilitiesCurrent | $72.3M | 2025-12-31 | 2026-03-04 | 10-K | 26-023444 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| 19 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$1.2B | 2025-12-31 | 2026-03-04 | 10-K | 26-023444 |
| 20 | operating income | us-gaap:OperatingIncomeLoss | -$170.1M | 2025-12-31 | 2026-03-04 | 10-K | 26-023444 |
| 21 | book equity | us-gaap:StockholdersEquity | $57.2M | 2025-12-31 | 2026-03-04 | 10-K | 26-023444 |
| 22 | liabilities | us-gaap:Liabilities | $189.2M | 2025-12-31 | 2026-03-04 | 10-K | 26-023444 |
| 23 | depreciation amortization | us-gaap:Depreciation | $26,000 | 2024-12-31 | 2026-03-04 | 10-K | 26-023444 |
| 24 | interest expense | us-gaap:InterestExpense | $1.1M | 2025-12-31 | 2026-03-04 | 10-K | 26-023444 |
| 25 | revenue | us-gaap:Revenues | $30.9M | 2025-12-31 | 2026-03-04 | 10-K | 26-023444 |
| 26 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $10.0M | 2024-12-31 | 2025-03-20 | 10-K | 25-003372 |
| 27 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $2.6M | 2022-12-31 | 2025-03-20 | 10-K | 25-003372 |
| 28 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $2.1M | 2021-12-31 | 2023-03-14 | 10-K | 23-003738 |
| 29 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $28,000 | 2024-12-31 | 2026-03-04 | 10-K | 26-023444 |
| 30 | current assets | us-gaap:AssetsCurrent | $95.0M | 2024-12-31 | 2026-03-04 | 10-K | 26-023444 |
| 31 | current liabilities | us-gaap:LiabilitiesCurrent | $31.0M | 2024-12-31 | 2026-03-04 | 10-K | 26-023444 |
| 32 | current assets | us-gaap:AssetsCurrent | $143.7M | 2023-12-31 | 2025-03-20 | 10-K | 25-003372 |
| 33 | current liabilities | us-gaap:LiabilitiesCurrent | $26.4M | 2023-12-31 | 2025-03-20 | 10-K | 25-003372 |
| 34 | assets | us-gaap:Assets | $149.7M | 2023-12-31 | 2025-03-20 | 10-K | 25-003372 |
| 35 | assets | us-gaap:Assets | $95.0M | 2022-12-31 | 2024-03-14 | 10-K | 24-003250 |
| 36 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 87,835,106 | 2026-02-27 | 2026-03-04 | 10-K | 26-023444 |
| 37 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 51,486,705 | 2025-03-19 | 2025-03-20 | 10-K | 25-003372 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.